Evolent Q1 Revenue at $496.25M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Reports Q1 revenue $496.25M, consensus $534.04M. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "I am happy with the strong start to the year. We are on track with our plan and have had successful, on-time oncology launches at both Highmark and Aetna. As we look into 2027 and beyond, we remain focused on both extending our market leadership in oncology and addressing the big opportunity we have with AI, all while fulfilling our commitments to shareholders, employees and customers."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVH
Wall Street analysts forecast EVH stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.670
Low
5.00
Averages
9.33
High
16.00
Current: 4.670
Low
5.00
Averages
9.33
High
16.00
About EVH
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Evolent (EVH) Q1 2026 Earnings Call Transcript
See More
Evolent Health Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Evolent Health is set to release its Q1 2023 earnings on May 7 before market open, with a consensus EPS estimate of -$0.05, reflecting a significant year-over-year decline of 183.3%, indicating profitability challenges ahead.
- Revenue Expectations: The revenue estimate stands at $534.04 million, representing a 10.4% year-over-year growth, which, while modest, suggests ongoing demand in the healthcare sector and the company's efforts to maintain its market position.
- Historical Performance Review: Over the past two years, Evolent has exceeded EPS estimates 50% of the time and revenue estimates 75% of the time, indicating some capacity for outperforming expectations, although recent downward revisions raise concerns about future performance.
- Market Sentiment Shifts: In the last three months, EPS estimates have seen one upward revision and six downward adjustments, while revenue estimates have experienced five upward and seven downward revisions, reflecting analyst uncertainty regarding the company's outlook, particularly concerning EBITDA recovery.
See More
Evolent Health Reports Strong Q4 Results, Shares Rise 4.1%
- Earnings Beat: Evolent Health reported Q4 revenue of $468.7 million, a 27.5% year-over-year decline, yet this figure met analyst expectations, demonstrating the company's resilience in challenging conditions and boosting investor confidence.
- Positive Outlook: The company provided strong full-year revenue guidance, and despite having the slowest revenue growth among peers, the better-than-expected earnings and optimistic outlook drove the stock price increase, reflecting market recognition of its future potential.
- High Volatility: Evolent Health's shares have experienced 54 moves greater than 5% over the past year, with today's 4.1% rise indicating that the market considers this news significant, though it does not fundamentally alter perceptions of the business.
- Long-term Investment Challenges: The stock has declined 21.7% since the beginning of the year, currently trading at $3.05, which is 74.2% below its 52-week high of $11.79, highlighting the challenges faced by long-term investors.
See More
Evolent Health to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Evolent Health is set to announce its Q1 2026 financial results on May 7, 2026, before the market opens, which is expected to provide investors with critical financial data and operational performance insights.
- Conference Call Details: Following the earnings release, Evolent will host a conference call at 8 a.m. ET, where investors can participate by dialing 855.940.9467 or 412.317.6034 for international calls, ensuring to call 15 minutes prior for questions.
- Live Broadcast and Playback: The conference call will be broadcast live on Evolent's investor relations website, and an audio playback will be available for 90 days post-call, allowing investors who missed the live event to catch up on the discussion.
- Company Overview: Evolent Health specializes in achieving better health outcomes for individuals with complex conditions, aiming to transform healthcare delivery through proven solutions that simplify and reduce costs, serving a national base of leading payers and providers.
See More
Global X Uranium ETF Underperforms Today
- ETF Performance: The Global X Uranium ETF is down approximately 2.6% in Tuesday afternoon trading, indicating a weak performance that may undermine investor confidence in the uranium market.
- Weak Individual Stocks: Among the ETF's components, shares of Nano Nuclear Energy fell by about 9.6%, while Centrus Energy dropped by approximately 7.5%, suggesting a bearish sentiment surrounding these companies that could lead to capital outflows.
- Market Impact Analysis: The decline in the uranium ETF may reflect investor concerns about the nuclear energy sector's outlook, particularly in the context of global energy transitions, potentially influencing future investment decisions.
- Investor Sentiment Shift: As the uranium ETF underperforms, investors may reassess their allocations to nuclear-related assets, leading to increased market volatility and impacting overall investment strategies.
See More
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Evolent (EVH) Q1 2026 Earnings Call Transcript
See More
Evolent Health Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Evolent Health is set to release its Q1 2023 earnings on May 7 before market open, with a consensus EPS estimate of -$0.05, reflecting a significant year-over-year decline of 183.3%, indicating profitability challenges ahead.
- Revenue Expectations: The revenue estimate stands at $534.04 million, representing a 10.4% year-over-year growth, which, while modest, suggests ongoing demand in the healthcare sector and the company's efforts to maintain its market position.
- Historical Performance Review: Over the past two years, Evolent has exceeded EPS estimates 50% of the time and revenue estimates 75% of the time, indicating some capacity for outperforming expectations, although recent downward revisions raise concerns about future performance.
- Market Sentiment Shifts: In the last three months, EPS estimates have seen one upward revision and six downward adjustments, while revenue estimates have experienced five upward and seven downward revisions, reflecting analyst uncertainty regarding the company's outlook, particularly concerning EBITDA recovery.
See More
Evolent Health Reports Strong Q4 Results, Shares Rise 4.1%
- Earnings Beat: Evolent Health reported Q4 revenue of $468.7 million, a 27.5% year-over-year decline, yet this figure met analyst expectations, demonstrating the company's resilience in challenging conditions and boosting investor confidence.
- Positive Outlook: The company provided strong full-year revenue guidance, and despite having the slowest revenue growth among peers, the better-than-expected earnings and optimistic outlook drove the stock price increase, reflecting market recognition of its future potential.
- High Volatility: Evolent Health's shares have experienced 54 moves greater than 5% over the past year, with today's 4.1% rise indicating that the market considers this news significant, though it does not fundamentally alter perceptions of the business.
- Long-term Investment Challenges: The stock has declined 21.7% since the beginning of the year, currently trading at $3.05, which is 74.2% below its 52-week high of $11.79, highlighting the challenges faced by long-term investors.
See More
Evolent Health to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Evolent Health is set to announce its Q1 2026 financial results on May 7, 2026, before the market opens, which is expected to provide investors with critical financial data and operational performance insights.
- Conference Call Details: Following the earnings release, Evolent will host a conference call at 8 a.m. ET, where investors can participate by dialing 855.940.9467 or 412.317.6034 for international calls, ensuring to call 15 minutes prior for questions.
- Live Broadcast and Playback: The conference call will be broadcast live on Evolent's investor relations website, and an audio playback will be available for 90 days post-call, allowing investors who missed the live event to catch up on the discussion.
- Company Overview: Evolent Health specializes in achieving better health outcomes for individuals with complex conditions, aiming to transform healthcare delivery through proven solutions that simplify and reduce costs, serving a national base of leading payers and providers.
See More
Global X Uranium ETF Underperforms Today
- ETF Performance: The Global X Uranium ETF is down approximately 2.6% in Tuesday afternoon trading, indicating a weak performance that may undermine investor confidence in the uranium market.
- Weak Individual Stocks: Among the ETF's components, shares of Nano Nuclear Energy fell by about 9.6%, while Centrus Energy dropped by approximately 7.5%, suggesting a bearish sentiment surrounding these companies that could lead to capital outflows.
- Market Impact Analysis: The decline in the uranium ETF may reflect investor concerns about the nuclear energy sector's outlook, particularly in the context of global energy transitions, potentially influencing future investment decisions.
- Investor Sentiment Shift: As the uranium ETF underperforms, investors may reassess their allocations to nuclear-related assets, leading to increased market volatility and impacting overall investment strategies.
See More
